Scholarlink

<p>Current biologics and small-molecule inhibitors for autoimmune diseases often provide symptomatic relief but fail to restore immune tolerance, necessitating lifelong treatment with associated risks. Triptolide, a natural compound from <i>Tripterygium wilfordii</i> Hook F, exhibits a unique capacity for immune reprogramming, simultaneously suppressing pathogenic immunity while enhancing regulatory functions, positioning it as a potential ‘immune reset’ agent. However, its clinical translation is plagued by a narrow therapeutic window due to mechanism-based toxicity, creating a critical challenge of decoupling efficacy from toxicity. This review moves beyond a descriptive cataloguing of triptolide derivatives to provide a critical appraisal of the field’s progress in achieving this decoupling. We systematically evaluate the most promising candidates (e.g., LLDT-8, Minnelide, ZT01), not only examining their mechanisms but also analyzing why most stall in early development. By integrating mechanistic insights with clinical progress data, we dissect the structural determinants of toxicity and efficacy and propose a concrete future roadmap focused on rational drug design (e.g., novel targets like TAK1), targeted delivery systems, and biomarker-driven precision medicine to advance safe and effective triptolide-based therapies to the clinic.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

From immunosuppression to immune reprogramming: is triptolide a potential “immune reset” agent in autoimmune diseases?

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月27日

查看全文
  • Dehui Yu,
  • Hu Lin

摘要

Current biologics and small-molecule inhibitors for autoimmune diseases often provide symptomatic relief but fail to restore immune tolerance, necessitating lifelong treatment with associated risks. Triptolide, a natural compound from Tripterygium wilfordii Hook F, exhibits a unique capacity for immune reprogramming, simultaneously suppressing pathogenic immunity while enhancing regulatory functions, positioning it as a potential ‘immune reset’ agent. However, its clinical translation is plagued by a narrow therapeutic window due to mechanism-based toxicity, creating a critical challenge of decoupling efficacy from toxicity. This review moves beyond a descriptive cataloguing of triptolide derivatives to provide a critical appraisal of the field’s progress in achieving this decoupling. We systematically evaluate the most promising candidates (e.g., LLDT-8, Minnelide, ZT01), not only examining their mechanisms but also analyzing why most stall in early development. By integrating mechanistic insights with clinical progress data, we dissect the structural determinants of toxicity and efficacy and propose a concrete future roadmap focused on rational drug design (e.g., novel targets like TAK1), targeted delivery systems, and biomarker-driven precision medicine to advance safe and effective triptolide-based therapies to the clinic.